BioTalk Unzipped – Détails, épisodes et analyse
Détails du podcast
Informations techniques et générales issues du flux RSS du podcast.

BioTalk Unzipped
BioTalk Unzipped
Fréquence : 1 épisode/15j. Total Éps: 36

Classements récents
Dernières positions dans les classements Apple Podcasts et Spotify.
Apple Podcasts
🇬🇧 Grande Bretagne - lifeSciences
25/07/2025#94🇬🇧 Grande Bretagne - lifeSciences
24/07/2025#77🇬🇧 Grande Bretagne - lifeSciences
23/07/2025#62🇬🇧 Grande Bretagne - lifeSciences
22/07/2025#45🇬🇧 Grande Bretagne - lifeSciences
21/07/2025#34🇬🇧 Grande Bretagne - lifeSciences
20/07/2025#22🇬🇧 Grande Bretagne - lifeSciences
19/07/2025#28🇬🇧 Grande Bretagne - lifeSciences
18/07/2025#17🇬🇧 Grande Bretagne - lifeSciences
17/07/2025#9🇬🇧 Grande Bretagne - lifeSciences
16/07/2025#14
Spotify
Aucun classement récent disponible
Liens partagés entre épisodes et podcasts
Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.
See all- https://slip.stream
409 partages
- https://www.celerion.com/
83 partages
- https://www.samaritanspurse.org/
79 partages
- https://www.linkedin.com/in/chadbriscoe/
103 partages
- https://www.linkedin.com/in/gregoryaustin1/
100 partages
- https://www.linkedin.com/in/jonathon-t-hill/
14 partages
Qualité et score du flux RSS
Évaluation technique de la qualité et de la structure du flux RSS.
See allScore global : 43%
Historique des publications
Répartition mensuelle des publications d'épisodes au fil des années.
Great Advances in Cancer Research with Dr. Jim Shen
Saison 1 · Épisode 20
dimanche 1 septembre 2024 • Durée 37:19
In this episode (EP20) of BioTalk Unzipped, host Gregory Austin and co-host Dr. Chad Briscoe interview Dr. Jim Shen, the Executive Director and Head of Regulated Bioanalysis Operations at BMS. They discuss topics such as the advancements in cancer therapies, the integration of AI and mechanistic modeling in drug development, and the complexities of regulatory submissions. Dr. Shen shares his journey into bioanalysis and his passion for mass spectrometry.
Chapters
01:15 - Introduction, Background, and Passion for The American Cancer Society
03:46 - Advancements in Cancer Therapies, Opdualag
08:03 - From Small Molecule to Large to Hybrid
12:52 - NEW NEWS! - Halda Raises $126M for a New Targeted Cancer Therapy
18:30 - Dr. Shen’s Journey from Computers to Chemistry into Bioanalysis
27:00 - The Integration of AI and Mechanistic Modeling in Drug Development
34:30 - Navigating the Complexities of Regulatory Submissions
Takeaways
Advancements in cancer therapies, such as immunotherapy and antibody drug conjugates, have revolutionized the treatment landscape and improved patient outcomes.
The integration of AI and mechanistic modeling in drug development shows promise but is still in its infancy. More research and collaboration between software and hardware engineers are needed to fully realize its potential.
Navigating the complexities of regulatory submissions requires adherence to international guidelines and validation of analytical methods to ensure accuracy and precision.
Dr. Shen's journey into bioanalysis highlights the importance of pursuing your interests and finding enjoyment in your work, even if it may not align with your initial plans.
Sound Bites
"Advancements in cancer therapies have revolutionized the treatment landscape."
"Antibody drug conjugates are one of the most exciting and interesting types of molecules."
"The integration of AI and mechanistic modeling in drug development shows promise but is still in its infancy."
New News Story:
Startup Halda raises $126M to advance new type of targeted cancer therapy
https://www.biopharmadive.com/news/halda-series-b-riptac-prostate-cancer/723933/
How to reach us:
American Cancer Society
Dr. Jim Shen
Bristol Myers Squibb - https://www.bms.com/
Dr. Chad Briscoe
Gregory Austin
Images
ADC Mechanism of Action
https://www.researchgate.net/figure/General-structure-of-antibody-drug-conjugate_fig1_355319441
Keywords
Bioanalysis, Cancer, Oncology, Research, Drug Development, Compliance, Regulatory Compliance, AI, ADC, Antibody Drug Conjugates, immunotherapy, Pharmaceutical, Biotechnology, Podcast, Science, Pharmaceutical Science
The Future of Hybrid Healthcare: Insights from Zealic CEO Chuck Piccirillo
Saison 1 · Épisode 19
jeudi 15 août 2024 • Durée 39:31
In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe continue their conversation with Zealic CEO, Chuck Piccirillo. They delve into the unique challenges of the patient journey and the increasing demand for hybrid healthcare solutions that offer more flexibility. The discussion highlights the rise of virtual health, particularly in Europe, and introduces exciting developments in ion channels as a goldmine for new medicines. They also explore the financial intricacies of drug development, the importance of leadership through incremental steps, the value of in-person interactions, and hard-earned lessons in the industry. Finally, Chuck offers invaluable advice for entrepreneurs in the life sciences sector.
Chapters
00:17 - Adapting to what is unique in the patient journey.
07:08 - Push for hybrid solutions - more flexibility.
09:20 - Virtual health is emerging, especially in Europe.
14:02 - New News! - Ion Channels are a goldmine for new medicines
19:23 - The Financial Side of Drug Development
21:50 - Leadership - Incremental Steps, the Value of In-Person Interactions, Learning Hard Lessons
30:58 - Advice For Entrepreneurs in Life Science
Takeaways
- Building blocks to build the digital patient experience, then tweak it to the individual drug and form a complex digital and personal adaptive health journey.
- The healthcare industry needs to find a balance between safety and innovation to ensure patients have access to the best possible care. Remote patient monitoring and decentralized clinical trials are crucial in improving patient engagement and outcomes in the healthcare industry.
- Virtual visits and technology integration can enhance patient engagement and make healthcare more accessible.
- While there has been an increase in decentralized trials, the focus is currently on commercial solutions due to the crowded nature of the clinical trial technology space.
- Virtual health and routine monitoring have the potential to alleviate the burden on healthcare providers and improve patient care.
- Ion channel research holds promise for developing new medicines and treatments for various conditions.
- Incremental progress and persistence are key in entrepreneurship and leadership.
Sound Bites
- (regarding adaptability in clinical software) “Imagine if LinkedIn only every 6 months. How engaging would that be?”
- "And it would actually integrate with like Uber, for example, and help them get a ride if they had to go to the doctor and actually, and all of that is based on these building blocks that we're able to assemble and then press a button."
- “I think everybody wants whatever aspect of life nowadays to be hybrid anything.”
- “It’s why we always talk about pragmatic innovation.”
- “Persistence in the face of opposition of all sorts.”
New News Story: These microscopic tunnels are a goldmine for new medicines
https://www.biopharmadive.com/news/ion-channels-drug-research-vertex-biohaven-jazz/719337/
How to reach us:
Crohn's & Colitis Foundation
https://www.crohnscolitisfoundation.org/
Chuck Piccirillo
https://www.linkedin.com/in/cpiccirillo/
Zealic Health - http://www.zealichealth.com
Dr. Chad Briscoe
https://www.linkedin.com/in/chadbriscoe/
Celerion - https://www.celerion.com/
Gregory Austin
https://www.linkedin.com/in/gregoryaustin1/
ECI - https://eci-rx.com /
Keywords
Patient Journey, Hybrid Healthcare Solutions, Drug Development Finance, Leadership in Life Sciences, Entrepreneurship in Life Sciences, Remote Patient Monitoring, Decentralized Clinical Trials, Healthcare Technology Integration, Digital Patient Experience, Clinical Software Adaptability, Pragmatic Innovation, Persistence in Entrepreneurship, Leadership
#HealthcareInnovation
#VirtualHealth
#DrugDevelopment
#LifeSciences
#Entrepreneurship
#DigitalHealth
#HybridHealthcare
#IonChannels
#PatientCare
#RemoteMonitoring
#ClinicalTrials
#Leadership
#HealthTech
#PragmaticInnovation
#Persistence
#pharmaceutical
#biotech
#science
#CEO
Breakthrough in Melanoma, Rare Diseases, and Curative Therapies with Scott Schliebner
lundi 15 avril 2024 • Durée 36:43
Summary
In this episode, Scott Schliebner discusses the unique challenges and complexities of rare disease trials. He highlights the difficulties in recruiting patients, the multidisciplinary nature of care, and the importance of collaboration among various stakeholders. The role of AI in rare disease trials is also explored, with a focus on its potential for patient recruitment and data analysis.
Scott shares success stories in the field and discusses the expanding use of gene therapy to target multiple genes. The conversation concludes with a discussion on the recent FDA approval of Iovance's Amtogvy as the first T-cell therapy for a solid tumor, Melanoma. In this conversation, Scott discusses the potential of cell therapy in targeting solid tumors, particularly melanoma. He highlights the importance of expanding the use of cell therapy to other tumor types and the potential for curative treatments. The conversation also delves into the challenges and questions surrounding pricing and ethics in the gene and cell therapy space. The impact of curative therapies on quality of life and healthcare costs is explored, along with the success of curative therapies in hepatitis C. The high bar of clinical development and regulatory standards is discussed, as well as the potential for cost-effective treatments. The conversation concludes with advice for young professionals and established clinical professionals in the field of drug development.
Takeaways
Cell therapy shows promise in targeting solid tumors, such as the breakthrough in melanoma treatment, and has the potential to provide curative treatments for various cancer types.
The pricing and ethical considerations surrounding gene and cell therapy raise important questions about accessibility and affordability.
Curative therapies have the potential to significantly improve quality of life and reduce healthcare costs by eliminating the need for long-term treatments.
The success of curative therapies in hepatitis C demonstrates the potential for similar breakthroughs in other disease areas.
Young professionals interested in a career in clinical drug development should seek opportunities to gain experience and consider starting in roles such as clinical research coordinators or clinical research associates.
Rare Givers is a nonprofit organization that supports caregivers in the rare disease space.
Chapters
00:21 - Collaborative Approach in Rare Disease Trials
3:32 - The Role of AI in Rare Disease Trials
6:11 - Success Stories in Rare Disease Trials
11:34 - Expanding Gene Therapy to Target Multiple Genes
16:56 - New News: FDA Approval of Iovance's Amtagvi, The Breakthrough of IOVANCE for Melanoma
19:27 - Targeting Solid Tumors with Cell Therapy, Expanding the Potential of Cell Therapy
20:23 - The Impact of Curative Therapies on Quality of Life and Healthcare Costs
21:11 - Challenges and Questions around Pricing and Ethics
22:37 - Cures for Hepatitis C
23:25 - The High Bar of Clinical Development and Regulatory Standards
24:05 - Pricing Considerations for Different Cancer Types, The Potential for Cost-Effective Treatments
27:45 - Advice for Young Professionals in Clinical Drug Development
31:49 - Advice for Established Clinical Professionals
33:21 - Scott's Hobbies and Interests
Learn about and DONATE to Rare Givers:
https://www.raregivers.global/
How to reach us:
Scott Schliebner
https://www.linkedin.com/in/scott-schliebner-1087789/
Dr. Chad Briscoe
https://www.linkedin.com/in/chadbriscoe/
Gregory Austin
https://www.linkedin.com/in/gregoryaustin1/
New News Link:
https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor
Image Credits
Iovance, https://www.iovance.com/
FDA approved, https://www.tipranks.com/news/iovance-nasdaqiova-fda-approves-cell-therapy-stock-gains
Amtagvi, https://www.amtagvi.com/
Impact of AI in Rare Disease Trials with Scott Schliebner
lundi 1 avril 2024 • Durée 36:11
Impact of AI in Rare Disease Trials with Scott Schliebner
Summary
In this episode, the hosts welcome Scott Schliebner as their guest and kick off with a charitable act, donating to Rare Givers. They delve into the Epitomee weight loss capsule's potential impact, then shift to discussing the challenges of establishing a North American infrastructure for a MedTech CRO, navigating cross-cultural dynamics. Later, they investigate the transformative potential of AI and machine learning in clinical trials. Scott Schliebner weighs in on the intricacies of rare disease trials, emphasizing patient recruitment hurdles, interdisciplinary care, and stakeholder collaboration. The conversation also delves into AI's role in addressing these challenges, particularly in patient recruitment and data analysis.
#clinicaltrials #science #ai #raredisease #drugdevelopment
Takeaways
Rare Givers (https://www.raregivers.global/) is a nonprofit organization that supports caregivers in the rare disease space.
The Epitome weight loss capsule is an innovative medical device that tricks the body into feeling full, aiding in weight loss.
Building a North American infrastructure for a MedTech CRO requires navigating cultural differences and finding key leaders who can adapt to a startup environment.
AI and machine learning have the potential to transform clinical trials by improving drug discovery, analyzing large datasets, and enhancing patient retention.
Chapters
00:00 - Introduction and Charity Donation - Rare Givers
02:30 - Discussion on Rare Givers
04:08 - What inspired Scott to the Clinical space
06:12 - New News: Epitomee Weight Loss Capsule
11:25 - Epitomee target drug delivery application weight loss competition with Wegovy
14:05 - Building a North American infrastructure for EU-based MedTech focused CRO
16:35 - Cultural idiosyncrasies to be aware of doing business with different countries
23:53 - The Impact of AI and Machine Learning, and generative AI in Clinical Trials, drug development, FDA compliance, and quality control
30:13 - Understanding Rare Disease Trials, and overcoming challenges
33:12 - Is it a Zebra or a Horse?
DONATE to Rare Givers:
https://www.raregivers.global/
How to reach us:
Scott Schliebner
https://www.linkedin.com/in/scott-schliebner-1087789/
Dr. Chad Briscoe
https://www.linkedin.com/in/chadbriscoe/
Gregory Austin
https://www.linkedin.com/in/gregoryaustin1/
New News Link:
Epitomee® announces the filing of a novel Weight Loss Capsule for FDA clearance
NIH Study publication: Safety, tolerability and efficacy of a novel self‐use biodegradable device for management of obesity
Image Credits
Zebra - https://www.rarediseaseday.org/event/6th-annual-rare-disease-day-virtual-race/
Invaluable Lessons in Leadership and Science with Dr. Russell Grant
vendredi 15 mars 2024 • Durée 43:27
Description:
In Episode 8 of BioTalk Unzipped, we dive deep into the scientific mind of Dr. Russell Grant, exploring how he navigates groundbreaking publications with a healthy dose of skepticism. From microsampling blood spots to dissecting experimental execution gaps, Dr. Grant reveals his strategies for separating scientific sizzle from substance.
In our latest segment of "New News," we discuss Elon Musk's Neurolink gaining FDA approval for clinical trials, sparking debates about neuroscience's role in the 21st century. With insights into the risks and rewards of understanding brain biochemistry, this episode challenges conventional thinking.
Discover the secrets behind Dr. Grant’s legendary leadership with the Triangle Area Mass Spec (TAMS) group, where mentorship, empowerment, and strong networks bridge academia and industry. Uncover how Dr. Grant encourages scientists to stay focused on foundational processes while striving for brilliance in their work.
From unexpected breakthroughs in sensitive testosterone measurements to fostering career development in his team, Dr. Grant shares invaluable lessons in leadership and personal growth. Tune in for memorable quotes, career insights, and a glimpse into Dr. Grant's life beyond the lab.
Join us as we unzip the world of science with Dr. Russell Grant on BioTalk Unzipped!
#biotechnology #diagnostics #science #innovation #leadership #pharmaceutical
SEGMENTS:
1:22 - What does Russ Grant’s brain do when he sees a groundbreaking publication? 7:47 - New News!
13:10 - Dr. Grant’s leadership with the TAMS (Triangle Area Mass Spec) group and why it’s so successful.
24:05 - Has the challenges for grad students changed in the past 2 decades?
26:49 - When Russ’ work led to something truly unexpected,
30:56 - Leadership in career development and the people they lead
35:51 - More memorable quotes
37:30 - What Russ does for fun.
How to reach us:
Dr. Russell Grant
https://www.linkedin.com/in/russell-grant-5144a26/
Dr. Chad Briscoe
https://www.linkedin.com/in/chadbriscoe/
Gregory Austin
https://www.linkedin.com/in/gregoryaustin1/
Conferences mentioned:
ASMS - https://www.asms.org/
MSACL - https://www.msacl.org/
ADLM - https://www.myadlm.org/
TAMS, Triangle Area Mass Spectrometry Discussion Group - https://tamsgroup.org/
New News Link:
Image Credits
Client Eastwood, Firefox - https://www.youtube.com/watch?v=eJJXIcig2h8
Neuralink - https://dig.watch/updates/neuralinks-first-human-implant-shows-promising-results
Tricorder Tech: That Star Trek Medical Scanner Is Getting Much Closer
Neuralizer - https://meninblack.fandom.com/wiki/Neuralyzer
Revolutionizing Diagnostic Patient Care with Dr. Russell Grant
vendredi 1 mars 2024 • Durée 33:03
Join us for Episode 7 of our podcast as we delve into the fascinating journey of Dr. Russell Grant, from the UK to America, navigating through large pharma to the field of diagnostics. Discover the nuances between bioanalytical approaches in clinical trials versus clinical healthcare, and Russ's insights on GLP environments. Learn how Russ tackled the challenges of COVID, and hear the incredible New News breakthrough in restoring hearing in an 11-year-old using gene therapy. Russ shares his American dream, his passion for diagnostics, and his thoughts on scientific integrity. Tune in for a captivating discussion on the critical role of diagnostics in saving lives and the pursuit of scientific excellence.
#biotechnology #diagnostics #science #innovation #patientcare
SEGMENTS:
1. Transitioning Across Continents: A Tale of Professional Evolution - From the UK to America, Exploring Pharma to Diagnostics.
2. Navigating Bioanalytics: Unraveling the Contrast Between Clinical Trials and Healthcare Applications, with a Focus on Mass Spec.
3. Efficiency in Action: Revolutionizing Patient Care by Shaving Seconds Off Injections, One Assay at a Time.
4. COVID Chronicles: Dr. Russel Grant's Vital Role Amidst the Pandemic's Chaos.
5. New News!: A Landmark Achievement in Gene Therapy Unveiled.
6. Crossing Borders: Dr. Russel Grant's Journey to America - Dreams, Challenges, and Triumphs.
7. Fueling Passion: Understanding Russ' Zeal for the Field of Diagnostics.
8. The Power of Diagnosis: Unveiling How Diagnostics Serve as Lifelines in Healthcare.
9. Navigating Integrity: A Candid Discussion on Scientific Literature, Academic Fraud, and the Path Forward for Scientists.
Connect with:
Dr. Russell Grant: https://www.linkedin.com/in/russell-grant-5144a26/
Dr. Chad Briscoe: https://www.linkedin.com/in/chadbriscoe/
Gregory Austin: https://www.linkedin.com/in/gregoryaustin1/
New News link:
Lilly makes waves, says gene therapy restores hearing for child with genetic hearing loss
Image Credits:
David Gilmour (Getty Images)
Sir Isaac Newton, https://en.wikipedia.org/wiki/Isaac_Newton
False Positives In The AI Explosion with Dr. Stephanie Pasas Farmer
jeudi 15 février 2024 • Durée 33:55
Welcome to Episode 6 of our podcast featuring Dr. Stephanie Pasas Farmer! 🎙️ Join us as we delve into the intricate world of data integrity, unveiling new software tools and the transformative impact they bring. Discover how virtual audits post-COVID, coupled with cloud security measures, are reshaping the landscape. 🔍
Explore the regulatory challenges amidst the technology and the AI explosion, with insights into the FDA's evolving role and its mission for public safety. Learn how ChatGPT transcends boundaries, from revolutionizing travel planning to enhancing workplace productivity. 💼
Delve into the nuances of ChatGPT's capabilities and limitations, navigating the fine line between its potential and pitfalls. Uncover concerns surrounding AI detectors in academia and the intricate realm of Deep Fakes. 🤖
Step into the conversational realm of ChatGPT, contrasting its prowess with conventional assistants like Alexa.
Follow Dr. Stephanie Pasas Farmer's impactful journey, from combating malaria in South Africa to her unique career trajectory. 🌍
Tune in as she shares the most surprising moments of her career and imparts invaluable advice for aspiring scientists and entrepreneurs. Don't miss out on this riveting exploration of innovation, integrity, and entrepreneurship in the scientific realm! 🚀
#Science #ChatGPT #Innovation #Entrepreneurship #LifeScience #SoftwareTools #FDA #AI #CareerAdvice
01:00 - Data integrity concerns and new software tools.
05:43 - How are Regulators dealing with this technology and AI explosion? Regulatory Challenges and FDA’s Role. FDA agents speaking about AI at conferences.
10:00 - Using ChatGPT in your non-work life for things like Travel Planning.
13:15 - Using ChatGPT for Work.
14:40 - Limitations of ChatGPT.
16:19 - Concerns about False Positives for AI detectors in academics and Deep Fakes, which are so difficult to detect.
17:13 - The Conversational Nature of ChatGPT.
19:57 - Stephanie’s Work in South Africa. She helps a non-profit for malaria and unmet medical needs globally. Building out the laboratory capabilities there. .
22:22 - The most surprising thing in her career. Advice for Aspiring Scientists and Entrepreneurs.
Dr. Stephanie Pasas Farmer: https://www.linkedin.com/in/stephanie-pasas-farmer/
spfarmer@bdatasolutions.com
Ariadne Software: https://www.ariadnesolutions.com/
BioData Solutions: https://www.bdatasolutions.com/
Dr. Chad Briscoe: https://www.linkedin.com/in/chadbriscoe/
Gregory Austin: https://www.linkedin.com/in/gregoryaustin1/
Image Credits
KU basketball, stubhub, https://www.stubhub.com/kansas-jayhawks-basketball-tickets/performer/6849
BTS, https://www.teenvogue.com/story/bts-billboard-music-awards-2018
Cardi B, https://www.xxlmag.com/cardi-b-reacts-criticism-not-dropping-album-tour/
Taylor Swift, https://www.tiktok.com/discover/You-broke-my-hand-and-you-didnt-even-seems-sorry-taylor-swift
Costa Rica, https://www.pixelstalk.net/
Deep fake, https://www.trymaverick.com/blog-posts/are-deep-fakes-all-evil-when-can-they-be-used-for-good
Africa, https://en.wikipedia.org/wiki/Africa
WRIB, https://www.wrib.org/
AAPS, https://www.aaps.org/home
APA, https://www.bostonsociety.org/APA/
How To Start A Company In Bioanalysis with Dr. Stephanie Pasas Farmer
jeudi 1 février 2024 • Durée 27:35
🎙️ Episode 5 of BioTalk Unzipped is here! Join hosts Gregory Austin and Dr. Chad Briscoe as they chat with Dr. Stephanie Pasas Farmer, founder of Ariadne Software and BioData Solutions. Explore the origins of Stephanie's companies, and the creation of RedThread, an AI-Enabled Auditing Tool that blends human intelligence with AI.
🧠 Dive into the practical side of Stephanie's software and the ever-evolving landscape of machine learning regulations. Get a glimpse into Stephanie's perspective on machine learning vs. expert systems and the challenges of navigating this dynamic field.
🌐 Discover what lies ahead for AI in Stephanie's software and the integration of her companies. The conversation extends to QPCR Analysis, exploring the monitoring of DNA and RNA for safety and efficacy. Uncover the resurgence of PCR technology with new applications.
🔍 Join us for a casual chat packed with insights, anecdotes, and a peek into the future of bioanalysis. Tune in now and enjoy the exploration of BioTech innovation with BioTalk Unzipped! 🧬🎧 #biotechnology #AIInnovation #Podcast #pharmaceutical #science
Segment list:
3:22 - Journey into Bioanalysis
7:56 - Stephanie starting her own company - Ariadne Software - the problem that inspired a company
12:44 - RedThread: An AI-Enabled Auditing Tool - human augmented intelligence
15:54 - What is the learning aspect of the software? Vigilante Computer Scientist? Regulations for machine learning.
19:04 - Machine Learning vs. Expert Systems. Machine learning analysis
20:52 - What is next for AI in Stephanie’s software and combining her companies.
22:23 - Expanding into QPCR Analysis. Monitoring DNA and RNA, safety and efficacy.
25:05 - PCR - what’s old is new again based on new applications.
Dr. Stephanie Pasas Farmer: https://www.linkedin.com/in/stephanie-pasas-farmer/
Ariadne Software: https://www.ariadnesolutions.com/
BioData Solutions: https://www.bdatasolutions.com/
Dr. Chad Briscoe: https://www.linkedin.com/in/chadbriscoe/
Gregory Austin: https://www.linkedin.com/in/gregoryaustin1/
Image Credits
KU logo, https://www.amazon.com/Open-Road-Brands-Jayhawk-Framed/dp/B07QJ4CK32
KU banner, https://www.amazon.com/Kansas-Jayhawks-Chalk-University-College/dp/B005RON6UA
Sickle Cell Breakthrough and Heartbreaking Stories with Dr. Russ Weiner
lundi 15 janvier 2024 • Durée 35:46
In Episode 4, (Part 2 of our conversation with Dr. Russ Weiner - a top scientific leader at Takeda), we boldly explore the Cell and Gene Therapy Industry, questioning its trajectory and potential impact on insurance companies.
Shifting focus, we delve into a groundbreaking Sickle Cell Therapy breakthrough, discussing its triumphs, challenges, and the crucial aspect of affordability. Despite the hurdles faced by payers and insurance companies, we find inspiration in the thrill of witnessing healing.
Discover the role of AAPS in shaping the biotech future and efforts to engage students. Episode 4 also highlights Russ’ passions, including a heartfelt case study and insights into his AAPS Presidential platform. Explore surprising career moments, the transformative power of AI, and personal aspects of Russ’ life, from scuba diving to family.
The episode concludes with valuable advice on mentoring, self-worth, and navigating the intricacies of career development.
Join us on BioTalk Unzipped for a captivating journey where science meets stories, leaving you enlightened and inspired.
#biotechnology #AI
#careerdevelopment #cellgenetherapy #science #career
SEGMENTS
1:15 - Be Brutal to the Cell and Gene Therapy Industry - Where is CGT really going? Will it bankrupt insurance companies?
3:50 - Sickle Cell Therapy breakthrough, side effects, and affordability
4:22 - Difficulty for payers, insurance companies, but the thrill of people getting healed
8:20 - Role in AAPS. Bringing in students to AAPS.
10:16 - Russ’ #1 Passion and a Heartbreaking case study of a young woman.
11:06 - Russ’ #2 Passion and his AAPS Presidential platform and amazing science done outside the US
15:07 - What we need to do to help the world and realities we don’t often see
17:51 - What’s the most surprising thing in Russ’ career?
19:31 - AI changed everything
23:43 - Russ’ other passions: scuba diving and family
27:37 - Funny stories and knowing your worth
29:24 - Always mentoring and always find a mentor
31:09 - Who’s in charge of your career?
33:51 - The difference between career development and promotion
How to find our guest, Dr. Russ Weiner, Head Oncology and Cell Therapy Clinical Biomarker Sciences and Operations at Takeda:
https://www.linkedin.com/in/russellweiner/
Your BioTalk Unzipped Cohosts:
Gregory Austin, Business Development Manager at ProPharma Group
https://www.linkedin.com/in/gregoryaustin1/
Dr. Chad Briscoe, Executive Vice President of Global Bioanalytical Services at Celerion
https://www.linkedin.com/in/chadbriscoe/
Image credits:
Image by Tumisu from Pixabay
Giphy: The Chemical Brothers; PBS Digital Studios; http://www.gizmodo.com.au/2015/07/did-an-australian-university-just-say-wi-fi-gives-you-and-your-kids-cancer/;
http://dynamicoceans.tumblr.com/post/99418047836/manta-ray-glittering-in-the-sunlight-despite
Photo by Andres Siimon on Unsplash
Tenor
AAPS
Cardiac cell beating courtesy of IGI Deputy Director Bruce Conklin
Liquid Diving Adventures, https://www.liquiddivingadventures.com/blog/post/2020/11/27/socorro-islands-mexico-only-by-liveaboard
Miraculous Cures: From Hospice to Survivor with Dr. Russ Weiner
mardi 2 janvier 2024 • Durée 36:54
In Episode 3 of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe dive deep into the world of biotech with an exclusive interview featuring the esteemed Dr. Russ Weiner. As a senior-level biopharmaceutical professional with over 30 years of hands-on experience, Dr. Weiner shares invaluable insights into pharmaceutical and biologic drug discovery/development, clinical trial conduct, and project leadership. The episode unfolds with a detailed exploration of Dr. Weiner's impressive career, starting with his journey into the industry and an incredible success story in hospice care. The conversation transitions into the dynamic changes witnessed in the past three decades, particularly the pivotal shift into biologics. Dr. Weiner's experiences with large molecules, mass spec, and the challenges faced in the evolving CRO space are discussed. Key Highlights: **Podcast Episode 3 Tracks, Miraculous Cures: From Hospice to Survivor** 🔬 1:36 - Russ’ Bio: Delve into the professional journey of Dr. Russ Weiner, a senior-level biopharmaceutical professional with over 30 years of hands-on experience. 🌟 4:29 - What Got You into This Industry?: Uncover the motivations and inspirations that led Dr. Weiner to a distinguished career in the biotech industry. 🏥 6:29 - Hospice Success: Explore a noteworthy success story from Dr. Weiner's career, shedding light on the impact of his work. 🔄 8:08 - Changes in the Past 30 Years: Trace the dynamic changes in the biotech industry over the last three decades, with a spotlight on the significant move into biologics. 🌐 12:30 - Biggest Challenges in Biologics: Dr. Weiner discusses the current hurdles in biologics, including pre-analytics, training, and the logistics of sample handling. 🦠 16:00 - COVID's Impact on the Process: Gain insights into how the COVID pandemic has influenced the biotech process and its day-to-day operations. 🌦️ 19:20 - Weather's Effect on Science: Explore how weather conditions can impact scientific processes in biotech. 🤝 21:30 - Improved Communication: Dr. Weiner reflects on the enhanced communication between sponsor companies, CROs, and laboratories in the biotech ecosystem. 🏗️ 24:00 - Building Labs and Transformational Leadership: Uncover what drives Dr. Weiner's role as a builder of labs and a transformational leader, emphasizing his passion for both science and leadership. 👥 26:00 - Building Cohesive Lab Teams: Gain insights into Dr. Weiner's approach to building cohesive and successful lab teams. 🌟 29:37 - Success Tips for Young Leaders: Dr. Weiner shares valuable advice for aspiring young leaders on how to achieve success in the dynamic field of biotech. 🏢 32:40 - Russ’ Career at Takeda: Explore Dr. Weiner's impactful career at Takeda Oncology, touching on his experiences in a start-up-like environment and his strategies for supporting his team. 🎙️ **Subscribe for more exclusive content and in-depth conversations in the world of biotech! 🚀 #BiotechJourney #LeadershipStories #BioTalkUnzippedPodcast #biotechnology #pharmaceutical #science #interview #hospice